How India Exports Syringe to the World

The U.S. Food and Drug Administration (FDA) maintains the Orange Book, which lists approved drug products and their therapeutic equivalence evaluations. As of March 2026, the Orange Book includes several approved Abbreviated New Drug Applications (ANDAs) for pre-filled syringes containing various medications. For instance, the FDA has approved ANDAs for pre-filled syringes delivering drugs such as enoxaparin sodium and adalimumab. These approvals indicate a well-established regulatory pathway for generic pre-filled syringes in the U.S. market.

Indian pharmaceutical companies have been active in this domain, with 291 exporters contributing to a total export value of $179.9 million USD for syringes (HS Code: 30049099) between 2022 and 2026. The United States emerged as the primary destination, accounting for 36.7% of these exports. This substantial market share underscores the importance of adhering to FDA regulations, including compliance with Current Good Manufacturing Practices (cGMP) and the submission of comprehensive ANDAs.

In the European Union (EU) and the United Kingdom (UK), pre-filled syringes are regulated as combination products, encompassing both the medicinal product and the device component. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) require a Marketing Authorization (MA) for such products. Applicants must demonstrate compliance with EU Good Manufacturing Practice (GMP) guidelines, which include stringent quality control measures for both the drug substance and the device.

Recent regulatory actions highlight the importance of device compatibility and safety. In January 2026, the MHRA issued a Class 2 Medicines Recall for Paliperidone Mercury Pharma prolonged-release suspension for injection in pre-filled syringes due to Good Manufacturing Practice deficiencies cited during a recent inspection at the finished product manufacturing site. (cpe.org.uk) Such incidents underscore the necessity for exporters to ensure that their products meet all regulatory requirements to maintain market access.

The World Health Organization (WHO) includes certain medications administered via pre-filled syringes in its Model List of Essential Medicines, recognizing their importance in global health. While the WHO Prequalification Programme primarily focuses on medicines, it also assesses the quality of medical devices, including syringes, to ensure they meet international standards.

Pre-filled syringes must comply with pharmacopoeial standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These standards specify requirements for the drug substance, formulation, and device components, ensuring product quality and safety.

In India, the Central Drugs Standard Control Organization (CDSCO) classifies pre-filled syringes based on their contents. For instance, if the syringe contains a Schedule H drug, it is subject to prescription-only regulations. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), may set ceiling prices for certain medications; however, as of March 2026, specific ceiling prices for pre-filled syringes are not listed.

Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceuticals, ensuring compliance with national regulations and facilitating international trade.

The patent landscape for pre-filled syringes varies depending on the drug substance and device technology. While some pre-filled syringes are protected by patents covering the formulation or delivery mechanism, others may be off-patent, allowing for generic competition. Exporters should conduct thorough patent searches to assess the risk of infringement and identify opportunities for market entry.

In January 2026, the MHRA issued a Class 2 Medicines Recall for Paliperidone Mercury Pharma prolonged-release suspension for injection in pre-filled syringes due to Good Manufacturing Practice deficiencies cited during a recent inspection at the finished product manufacturing site. (cpe.org.uk)

In August 2015, the MHRA issued a medical device alert for Medicina Ltd's automatically retracting safety syringes, including insulin syringes, due to risks of needle stick injury and incorrect shelf life information. (diabetes.org.uk)

These developments underscore the importance of stringent quality control and regulatory compliance for manufacturers and exporters of pre-filled syringes.

India's pharmaceutical industry, including syringe manufacturing, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these critical components are sourced from China, underscoring a significant dependency. This reliance exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade restrictions, or production disruptions in China.

To mitigate this risk, the Indian government initiated the Production Linked Incentive (PLI) scheme in October 2024, aiming to bolster domestic production of essential APIs and KSMs. By November 2024, two greenfield plants were inaugurated under this scheme to manufacture key molecules like Penicillin G and Clavulanic Acid, marking a strategic move to reduce import dependence. However, the full impact of these initiatives on reducing dependency remains to be seen, as establishing self-sufficiency in API production is a long-term endeavor.

The export data for syringes from India reveals a high supplier concentration, with the top five exporters accounting for 84.6% of the total export value. Notably, GLAND PHARMA LTD alone contributes 34.7% of exports, indicating a significant reliance on a limited number of suppliers. Such concentration poses a risk of supply disruptions if any of these key players face operational challenges.

The PLI scheme, launched in October 2024, aims to diversify and strengthen the supplier base by incentivizing domestic production of critical pharmaceutical components. While this initiative is a positive step, its effectiveness in reducing supplier concentration in the syringe export sector will depend on the successful establishment and scaling of new manufacturing units.

Recent geopolitical events have significantly impacted global shipping routes. In March 2026, escalating conflicts in the Middle East led to the effective closure of the Strait of Hormuz, a vital passage for global trade. This disruption caused a sharp decline in maritime transit, with tanker traffic dropping by approximately 70% and over 150 ships anchoring outside the strait to avoid risks. The closure has been described as the largest disruption to the energy supply since the 1970s energy crisis.

Additionally, tensions in the Red Sea and the Strait of Hormuz have led to increased shipping risks, with some tankers avoiding these routes due to heightened security concerns. These disruptions have led to surging freight rates and potential delays in the delivery of raw materials and finished products, affecting the global supply chain, including the export of syringes from India.

• Diversify API and KSM Sources: Expand sourcing strategies to include multiple countries and domestic suppliers to reduce dependency on any single nation, particularly China.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme and similar initiatives to bolster local manufacturing capabilities for critical pharmaceutical components.

• Strengthen Supplier Base: Encourage the development of a broader network of syringe manufacturers to mitigate risks associated with high supplier concentration.

• Monitor Geopolitical Developments: Establish a dedicated team to track and assess geopolitical events that could impact shipping routes and supply chains, enabling proactive responses.

• Develop Contingency Plans: Create and regularly update contingency plans to address potential disruptions in raw material supply and shipping logistics, ensuring business continuity.

RISK_LEVEL: HIGH